Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 10:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 2,486 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Interventions
VAX014, Nivolumab or pembrolizumab
Drug · Combination Product
Lead sponsor
Vaxiion Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Conditions
Neoplasms, Lymphoma
Interventions
LMP400, LMP776
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Incurable Solid Malignancy
Interventions
Vandetanib, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Leonard Appleman
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

NCT02671435
Conditions
Advanced Solid Tumors
Interventions
Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 19 more
Conditions
Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
Interventions
TT-10, TT-4
Drug
Lead sponsor
Portage Biotech
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bryostatin 1, cisplatin
Drug
Lead sponsor
Lombardi Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Neoplasms, Tumors, Solid Tumors, Metastatic Cancer
Interventions
EGFRBi-armed autologous activated T cells
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
JZP341
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Denver, Colorado • Sarasota, Florida • Baltimore, Maryland + 5 more
Conditions
Breast Cancer, Advanced Malignant Solid Tumors
Interventions
neratinib, vinorelbine
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
8
States / cities
Fayetteville, Arkansas • Duarte, California • Lebanon, New Hampshire + 5 more
Conditions
Solid Tumors
Interventions
indibulin
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Solid Tumors
Interventions
REC-7735
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Grand Rapids, Michigan • Irving, Texas • Fairfax, Virginia
Conditions
Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II, Colorectal Cancer for Phase II
Interventions
ribociclib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Fayetteville, Arkansas • Duarte, California • New Haven, Connecticut + 3 more
Conditions
Tumors
Interventions
satraplatin and docetaxel
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome
Interventions
SB939, Azacitidine
Drug
Lead sponsor
S*BIO
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Houston, Texas • Madison, Wisconsin
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
7-hydroxystaurosporine, cisplatin
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
4
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 1 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel, lenalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Tumors, Neoplasm Metastasis
Interventions
Rapamycin (sirolimus), Grapefruit Juice
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Refractory Multiple Myeloma, Stage III Multiple Myeloma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
2-methoxyestradiol, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Interventions
AVZO-021, Fulvestrant, Letrozole, AVZO-023
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Los Angeles, California • New Haven, Connecticut • Orlando, Florida + 12 more
Conditions
Tumors, Hypoxia
Interventions
TH-302
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Indianapolis, Indiana + 3 more
Conditions
Solid Tumors
Interventions
Bevacizumab, Dasatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Solid Tumor
Interventions
ABSK121-NX
Drug
Lead sponsor
Abbisko Therapeutics Co, Ltd
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
La Jolla, California • Detroit, Michigan • Las Vegas, Nevada + 1 more
Conditions
Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A, Locally Advanced Colorectal Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Trifluridine and Tipiracil Hydrochloride, Talazoparib Tosylate
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Advanced Solid Tumors
Interventions
TAS266
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Tampa, Florida • San Antonio, Texas • Salt Lake City, Utah